Combination treatment with irritant and recombinant interleukin 2 in the peritoneal cavity for evoking effective anti-tumor activity: generation of lymphokine-activated killer cells and tumor-specific killer cells.
Journal: 1990/August - Japanese journal of cancer research : Gann
ISSN: 0910-5050
PUBMED: 2114394
Abstract:
Meth A sarcoma, growing in the subcutaneous tissue of syngeneic BALB/c mice, regressed completely after an intraperitoneal (ip) injection of proteose peptone (PP) (on day 6) followed by 2 ip administrations (on days 7 and 8) of human recombinant interleukin-2 (IL-2, 25 micrograms/day), whereas one such treatment alone had little effect on the tumor growth. While this combination treatment was effective in anti-asialo GM1 antibody-treated mice, no such effect was noted in T cell-depleted ATXFL (thymectomized, irradiated and fetal liver cell-reconstituted) mice. These results show that T cells are mainly responsible for this antitumor effect. Treatment with a combination of PP and IL-2, but not with either PP or IL-2 alone, resulted in a marked increase in the T cell population in the peritoneal cavity after the treatment. At an early stage after the combination treatment, both peritoneal exudate cells (PEC) and spleen cells exhibited killing activity with a promiscuous specificity. However, at a later stage, 7 days after the treatment, Meth A-specific killer activity was observed in both PEC and the spleen. Meth A rechallenge was rejected by the mice in which the tumor had regressed, but the antigenically different Meth 1 was accepted by them. A similar result was obtained in Winn's neutralization test. These results suggest that this combination treatment, which is effective in the generation of lymphokine-activated killer cells in the peritoneal cavity, finally resulted in the induction of tumor-specific killer cells in the periphery. These results clearly show the anti-tumor efficacy of combination treatment with PP and rIL-2.
Open in
PUBMED | PMC | Google Scholar | Wikipedia
Relations:
Content
Citations
(1)
Diseases
(1)
Drugs
(1)
Chemicals
(5)
Organisms
(3)
Processes
(2)
Anatomy
(3)
Affiliates
(1)
Similar articles
Articles by the same authors
Discussion board
Japanese Journal of Cancer Research : Gann. Mar/31/1990; 81(4): 416-424
PMID: 2114394
PMC: 5918044

Combination Treatment with Irritant and Recombinant Interleukin 2 in the Peritoneal Cavity for Evoking Effective Anti‐tumor Activity: Generation of Lymphokine‐activated Killer Cells and Tumor‐specific Killer Cells

Abstract

Abbreviations:

IL‐2interleukin‐2PPproteose‐peptoneNKnatural killerLAKlymphokine‐activated killerPECperitoneal exudate cellsATXFLadult thymectomized, irradiated and reconstituted with fetal liver cells

References

  • 1. )Lotze,M. T.,Grimm,E. A.,Mazumder,A.,Strausser,J. L.andRosenberg,S. A.Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T‐cell growth factor.Cancer Res.,41,44220–4425(1981).[Google Scholar]
  • 2. )Grimm,E. A.,Mazumer,A.,Zhang,H. Z.andRosenberg,S. A.Lymphokine activated killer cell phenomenon. Lysis of natural killer‐resistant fresh solid tumor cell by interleukin 2‐activated autologous human peripheral blood lymphocytes.J. Exp. Med.,155,1823–1841(1982).[PubMed][Google Scholar]
  • 3. )Cheever,M. A.,Greenberg,P. D.,Fefer,A.andGills,S.Augmentation of the anti‐tumor therapeutic efficacy of long‐term cultured T lymphocytes by in vivo administration of purified interleukin 2.J. Exp. Med.,155,968–980(1982).[PubMed][Google Scholar]
  • 4. )Ettinghausen,S. E.,Lipford,E. H.,Mule,J. J.andRosenberg,S. A.Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine‐activated killer (LAK) cells.J. Immunol.,135,3623–3633(1985).[PubMed][Google Scholar]
  • 5. )Rosenberg,S. A.,Mule,J. J.,Spiess,P. J.,Reichert,C. M.andSchwarz,S. L.Regression of established pulmonary metastasis and subcutaneous tumor mediated by the systemic administration of high dose recombinant interleukin 2.J. Exp. Med.,161,1169–1188(1985).[PubMed][Google Scholar]
  • 6. )Donohue,J. H.andRosenberg,S. A.The fate of interleukin 2 after in vivo administration.J. Immunol.,130,2203–2208(1983).[PubMed][Google Scholar]
  • 7. )Mule,J. J.,Shu,S.,Schwarz,S. L.andRosenberg,S. A.Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin 2.Science,225,1487–1489(1984).[PubMed][Google Scholar]
  • 8. )Rosenberg,S. A.,Lotze,M. T.,Muul,L. M.,Leitman,S.,Chang,A. E.,Ettinghausen,S. E.,Matory,Y. L.,Skibber,J. M.,Shiloni,E.,Vetto,J. T.,Seipp,C. A.,Simpson,C.andReichert,C. M.Observations on the systemic administration of autologous lymphokine‐activated killer cells and recombinant interleukin 2 to patients with metastatic cancer.N. Engl. J. Med.,318,1485–1492(1985).[Google Scholar]
  • 9. )Terasaka,R.,Himeno,K.,Shiraishi,M.andNomoto,K.Characteristics of xenograft rejection. 1. Augmented cytotoxicity of peritoneal T cells after intraperitoneal injection of booster antigen and/or proteose peptone.Jpn. J. Exp. Med.,51,75–80(1981).[PubMed][Google Scholar]
  • 10. )Old,L. J.,Boyes,E. A.,Clarke,D. A.andCarswell,E. A.Antigenic properties of chemically induced tumors.Ann. N.Y. Acad. Sci.,101,80–106(1962).[Google Scholar]
  • 11. )Gomi,K.,Morimoto,M.andNomoto,K.Cytotoxic T‐cell‐mediated anti‐tumor effect of levamisole against murine syngeneic fibrosarcoma.Cancer Res.,42,4197–4202(1982).[PubMed][Google Scholar]
  • 12. )Naruo,K.,Hinuma,S.,Kato,K.,Koyama,M.,Tada,H.,Shiho,O.andTsukamoto,K.Comparison of the biological properties of purified natural and recombinant human interleukin 2.Biochem. Biophys. Res. Commun.,128,257–264(1985).[PubMed][Google Scholar]
  • 13. )Kato,K.,Yamada,T.,Kawahara,K.,Onda,K.,Asano,T.,Sugino,J.andKakinuma,A.Purification and characterization of recombinant human interleukin 2 produced in Escherichia coli.Biochem. Biophys. Res. Commun.,130,692–699(1985).[PubMed][Google Scholar]
  • 14. )Habu,S.,Fukui,H.,Shimamura,K.,Kasai,M.,Nagai,Y.,Okamura,K.andTamaoki,N.In vivo effects of anti‐asialo‐GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice.J. Immunol.,127,34–38(1981).[PubMed][Google Scholar]
  • 15. )Toshitani,A.,Taniguchi,K.,Kawano,Y.andNomoto,K.Inverse relationship in H‐2‐associated lysis between NK cells and rIL‐2‐activated killer cells: evidence from in vitro killing and metastatic experiments.Cell. Immunol.,108,188–202(1987).[PubMed][Google Scholar]
  • 16. )Brunner,K. T.,Mauel,J.,Rudolf,H.andChapuis,B.Studies of allograft immunity in mice. I. Induction, development, and in vitro assay of cellular immunity.Immunology,18,501–515(1970).[PubMed][Google Scholar]
  • 17. )Winn,H. J.Immune mechanisms in homotransplantation. II. Quantitative assay of the immunologic activity of lymphoid cells stimulated by tumor homografts.J. Immunol.,86,228–248(1961).[PubMed][Google Scholar]
  • 18. )Donohue,J. H.,Rosenstein,M.,Chang,A. E.,Lotze,M. T.,Robb,R. T.andRosenberg,S. A.The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma.J. Immunol.,132,2123–2128(1984).[PubMed][Google Scholar]
  • 19. )Fujimoto,S.,Greene,M. I.andSehon,A. H.Regulation of the immune response to tumor antigens. I. Immunosuppressor cells in tumor‐bearing hosts.J. Immunol.,116,791–799(1976).[PubMed][Google Scholar]
  • 20. )Hellström,I.,Sjögren,H. O.,Warner,G.andHellström,K. E.Blocking of cell‐mediated tumor immunity by sera from patients with growing neoplasms.Int. J. Cancer,7,226–237(1971).[PubMed][Google Scholar]
  • 21. )Sjögren,H. O.,Hellström,I.,Bansal,S. C.,Warner,G. A.andHellström,K. E.Elution of “blocking factors” from human tumor, capable of abrogating tumor cell destruction by specifically immune lymphocytes.Int. J. Cancer,9,274–283(1972).[PubMed][Google Scholar]
  • 22. )Yasumoto,K.,Miyazaki,K.,Nagashima,A.,Ishida,T.,Kuda,T.,Yano,T.,Sugimachi,K.andNomoto,K.Induction of lymphokine‐activated killer cells by intra‐pleural instillation of recombinant interleukin‐2 in patients with malignant pleurisy due to lung cancer.Cancer Res.,47,2184–2187(1987).[PubMed][Google Scholar]
  • 23. )Uchida,A.andMicksche,M.Intrapleural administration of OK‐432 in cancer patients. Activation of NK cells and reduction of suppressor cells.Int. J. Cancer,31,1–5(1983).[PubMed][Google Scholar]
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.